Company Events & EarningsCore researchlive in productionNew
Pdufa Label Type Drift
Updated dailyData needs: lowlong only
paper
2024
Source
Industry mechanism: PDUFA approval windows differ by label type (NME larger reprice than label expansion).
Read the paper →
In plain terms
FDA PDUFA approval dates for new drugs (vs label expansions) drive bigger price swings.
How it works
FDA PDUFA event window split by NME (first-time drug) vs label-expansion (repeat drug_name).
Live results
0 times picked on its own · 1 times inside a blend (1 beat the stock) · updated 2026-06-06This strategy is a frequent ingredient in blends that combine a few strategies on one stock. It has contributed to 1 such blended picks (1 of which beat simply holding the stock). Picking it on its own is only one of the ways it shows up.
How its picks scored vs. buy & hold
Each pick is graded on a recent year it was never tuned on, against simply owning the same stock
Where its edge concentrates
Share of picks in each company-size group that beat buy & hold
How often it trades
Active vs. patient. Bars on the left mean it waits for rare setups; bars on the right mean it trades often
Return vs. buy & hold
How much each pick beat or trailed simply owning the stock over the test year (extreme microcap moves trimmed)
Loading substrate evidence…
Data dependencies
- Fda adcomm
A data feed this strategy reads, refreshed on its normal schedule.
- Daily prices
Adjusted-close OHLCV for every US-listed ticker; primary price feed.
Expected edge
- Reported return
- ~5-15% per event
- Reported Sharpe
- ~0.5
- Tested over
- T-15d to T+30d
PDUFA events drive ~5-15% reprice; NMEs cluster in upper range.
Example tickers where this is likely to fire
Illustrative only, the signal fires based on the live data, not a fixed list.
Related families
Explore Pdufa Label Type Drift on alphactor.ai
See which tickers this family is currently firing on, with live signals and rankings.